metaMe Health Named to the 2022 CB Insights Digital Health Top 150 List

CB Insights has announced the fourth annual Digital Health 150.

CHICAGO, Dec. 9 – metaMe Health breaks into the top 150 of the most promising private digital health companies of 2022.By being recognized in CB Insights prestigious "Digital Health 150" list, metaMe Health is recognized by industry leaders worldwide for their achievements in pioneering prescription digital therapeutics (PDTs) for gastrointestinal conditions. It is the developer of Regulora®, which in 2021 became the first FDA-authorized PDT specifically for abdominal pain associated with irritable bowel syndrome in adults.

"We are honored to be a member of this year's CB Insights Digital Health 150 cohort," said Tim Rudolphi,CEO of metaMe Health. "To be included in the top 150 digital health companies highlights our growth trajectory, our significant pipeline of PDT products in development, and our focus on improving access to care for patients suffering with GI conditions."

The 2022 Digital Health 150 list was selected from a pool of over 13,000 private companiesbased on several criteria including; R&D activity, proprietary Mosaic scores, market potential, business relationships, investor profile, news sentiment analysis, competitive landscape, team strength, tech novelty, and a review of over 3,000 analyst briefings.

"From reimagining clinical care, to leveraging tech like AR/VR to improve surgical training, this year's Digital Health 150 winners are transforming the future of healthcare with digital technology," said Brian Lee, SVP of CB Insights' Intelligence Unit. "This increasingly global cohort, representing more than 18 countries across five continents, is not only driving better patient outcomes, but making healthcare more accessible. We are excited to follow the meaningful impact and continued success of this year's winners."

To find out more about Digital Health 150, please visit here.

About metaMe Health
metaMe Health, Inc., is a U.S. company that develops Prescription Digital Therapeutics (PDT) for the treatment of common chronic conditions. metaMe Health’s initial digital solutions aim to relieve the pain and disruption of everyday life experienced by millions suffering from gastrointestinal disorders. By allowing patients to be prescribed treatment confidentially and to undergo treatment privately at home, metaMe Health offers non-drug options that provide relief in a familiar, comfortable environment. For additional information, please visit or follow @metaMeHealth on Twitter and metaMe Health on LinkedIn.

About CB Insights

CB Insights builds software that enables the world's best companies to discover, understand, and make technology decisions with confidence. By marrying data, expert insights, and work management tools, clients manage their end-to-end technology decision-making process on CB Insights. To learn more, please visit here.

Quick facts on the 2022 Digital Health 150:

  • Equity funding and deals: Since 2017, this year's Digital Health 150 winners have raised around $5.6B in equity funding across 378 deals. This includes approximately $1.6B raised across 85 deals in 2022 YTD alone.
  • Unicorns: This year's list includes only 5 unicorns with a $1B+ valuation, around 3% of the total list. For comparison, last year's list contained 17. This tracks with a broader drop in new unicorns across sectors in 2022.
  • Global Reach: Winners in this year's Digital Health 150 span 18 countries across 5 continents. A quarter (25%) are headquartered outside of the US — the most in the history of this list. While the US still leads, the UK comes in second with 9 winners, followed by Canada with 5 and Brazil with 3.
Related Content
© 2023 MJH Life Sciences

All rights reserved.